Valneva (NASDAQ:VALN) Price Target Lowered to $15.00 at Guggenheim

Valneva (NASDAQ:VALN) had its price target lowered by Guggenheim from $17.00 to $15.00 in a research note released on Monday,Benzinga reports. Guggenheim currently has a buy rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $17.00 target price on shares of Valneva in a research report on Friday.

Valneva Price Performance

Shares of VALN stock opened at $7.43 on Monday. Valneva has a fifty-two week low of $3.62 and a fifty-two week high of $9.50. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78. The firm has a market capitalization of $603.77 million, a price-to-earnings ratio of -57.15 and a beta of 1.93. The stock’s 50-day simple moving average is $6.40 and its 200-day simple moving average is $5.59.

Valneva (NASDAQ:VALN) last released its earnings results on Thursday, March 20th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.32). Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. The company had revenue of $56.48 million for the quarter, compared to analysts’ expectations of $55.64 million. As a group, equities analysts forecast that Valneva will post 0.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Valneva

A hedge fund recently bought a new stake in Valneva stock. ABC Arbitrage SA acquired a new stake in shares of Valneva SE (NASDAQ:VALN) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 19,244 shares of the company’s stock, valued at approximately $84,000. 11.39% of the stock is owned by hedge funds and other institutional investors.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.